Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 5/20 | 0.75 |
| ▸ | BRD2 | P25440 | 2/20 | 0.75 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.75 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.75 |
| ▸ | PDE4A | P27815 | 7/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11401591 | 0.88 | MEN1 (0.81) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL7457891 | 0.87 | MEN1 (1.00) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11394726 | 0.87 | MEN1 (0.80) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11395669 | 0.86 | MEN1 (0.78) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11399416 | 0.86 | MEN1 (0.78) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL19066317 | 0.86 | BRD4 (1.00) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11399596 | 0.85 | MEN1 (0.95) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL10695216 | 0.82 | MEN1 (0.75) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL7999341 | 0.82 | MAPK1 (0.59) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| Denbufylline SCHEMBL7299526 | 0.81 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0485495-A1 | USE OF XANTHINE-DERIVATIVES AS INHIBITORS OF INDUCED BLOOD EOSINOPHILIA | Beecham Group p.l.c. (GB) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991001730-A2 | USE OF XANTHINE-DERIVATIVES AS INHIBITORS OF INDUCED BLOOD EOSINOPHILIA | BEECHAM GROUP PLC (GB) | 1991-02-21 | — | — | WO | disclosed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | disclosed |
| US-4657910-A | Treatment of cerebrovascular disorders and/or disorders associated with cerebral senility | BEECHAM-WUELFING GMBH & CO. KG (DE) | 1987-04-14 | — | — | US | disclosed |
| EP-0042706-B1 | XANTHINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR THEIR PREPARATION | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1985-12-27 | — | — | EP | disclosed |
| EP-0157098-A1 | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation | Beecham Wuelfing GmbH & Co KG (DE) | 1985-10-09 | — | — | EP | disclosed |
| US-4372959-A | TREATMENT OF PERIPHERAL VASCULAR DISEASE | BEECHAM-WULFING GMBH & CO. KG (DE) | 1983-02-08 | — | — | US | disclosed |
| EP-0042706-A2 | Xanthine derivatives, pharmaceutical compositions containing them and a process for their preparation | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1981-12-30 | — | — | EP | disclosed |